drugset / Trial / NCT03602027
Phase I Study of the Combination of Anlotinib With Gefitinib
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this clinical study is to evaluate the tolerability and toxicity of different dose of Anlotinib puls Gefitinib in First-line Treatment of Advanced Gene Positive Non-squamous Non-small Cell Lung Cancer , to provide a reference of dosage for Phase II clinical trials
Timeline
- Start
- 2018-08-01
- Primary completion
- 2018-12-01
- Completion
- 2019-02-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Catequentinib | Small molecule | 8 mg | Oral |
| Subject | Catequentinib | Small molecule | 10 mg | Oral |
| Subject | Catequentinib | Small molecule | 12 mg | Oral |
| Background | Gefitinib | Small molecule | 250 mg | Oral |